Oncogenic MicroRNAs: Key Players in Malignant Transformation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
MicroRNAs (miRNAs) represent a class of non-coding RNAs that exert pivotal roles in the regulation of gene expression at the post-transcriptional level. MiRNAs are involved in many biological processes and slight modulations in their expression have been correlated with the occurrence of different diseases. In particular, alterations in the expression of miRNAs with oncogenic or tumor suppressor functions have been associated with carcinogenesis, malignant transformation, metastasis and response to anticancer treatments. This review will mainly focus on oncogenic miRNAs whose aberrant expression leads to malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“Mutations in the TP53 gene are the most frequent type of gene-specific alterations in different human cancers [58].”
BackgroundApoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524 · cited 1×
“Defects in apoptotic pathway contribute to the occurrence of different human diseases, such as cancer [84].”
BackgroundCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 1×
“The extrinsic pathway requires the activation of death receptors anchored at the cell membrane through the binding of FasL, TNF and TRAIL ligands, which cause the recruitment and the oligomerization of Fas-Associated protein with Death Domain (FADD) within the Death-Inducing Signaling Complex (DISC), resulting in Casp…”
BackgroundRegulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · cited 1×
“Alterations in DNA, caused by genetic mutations determining structural and expression modification, at coding and non-coding regions, are responsible for cancer occurrence, gradual increase in tumor size, disorganization and malignancy [1].”
BackgroundUnique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023 · cited 1×
“Several studies have identified miRNA expression profiles specific to different human cancer types that also correlate with patient survival, suggesting the potential usefulness of miRNAs in cancer prediction, diagnosis and therapy [133–135].”
BackgroundTumour invasion and metastasis initiated by microRNA-10b in breast cancer
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06174 · Cited by 2,605 · cited 1×
“In particular, the expression of miR-10b is induced by the transcription factor Twist, which binds to the putative promoter of mir-10b [121].”
BackgroundTP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Most of these mutations (90%) are missense mutations that mainly reside in the exons encoding the p53 DNA-binding domain [59].”
BackgroundThe p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967 · cited 1×
“p53 protein acts as a transcriptional activator and regulates the expression of many target genes involved in different cellular processes, such as cell cycle arrest, apoptosis, DNA repair and senescence [57].”
Background
Cited by
miRNAs in Cancer (Review of Literature)
Smolarz, B., Durczyński, A., Romanowicz, H., Szyłło, K., & Hogendorf, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052805 · Cited by 296
Rojas, A., Añazco, C., González, I., & Araya, P. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy012 · Cited by 82
Mao, W., Wang, K., Wu, Z., Xu, B., & Chen, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02114-2 · Cited by 48
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
Choi, K. H., Shin, C. H., Lee, W. J., Ji, H., & Kim, H. H. (2019) · Bioscience Reports · doi:10.1042/bsr20190634 · Cited by 42
Metadata
- Authors
- Frixa, T., Donzelli, S., & Blandino, G.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2015-12-18
- Volume
- 7
- Issue
- 4
- Pages
- 2466-2485
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2216377839
- Cited by
- 147
- References
- 24
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncogenic MicroRNAs: Key Players in Malignant Transformation. https://app.cochat.ai/papers/10.3390/cancers7040904
- The paper
- Frixa, T., Donzelli, S., & Blandino, G. (2015). Oncogenic MicroRNAs: Key Players in Malignant Transformation. Cancers. https://doi.org/10.3390/cancers7040904
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.